NImmune Biopharma

NImmune Biopharma is a private, late-clinical-stage biotech based in San Diego, pioneering a novel approach to treating autoimmune diseases via the LANCL2 pathway. Its lead asset, omilancor, is positioned as a potential first- and best-in-class oral therapeutic for inflammatory bowel disease (IBD), with a Phase 3 readout expected in 2026. The company is led by a seasoned team with deep immunology and biotech development experience and utilizes a proprietary AI platform (TITAN-X) to identify targets and expand its pipeline. NImmune is pre-revenue and focused on advancing its clinical programs to address significant unmet needs in autoimmune conditions.

TITAN-X Precision Medicine A.I. Platform integrating AI, bioinformatics, and computational modeling for target and biomarker discovery; focused on the LANCL2 immunoregulatory pathway.

NImmune competes in the crowded IBD space against dominant anti-TNF biologics, newer oral agents (JAK inhibitors, S1P modulators), and emerging injectable biologics (anti-TL1A, anti-IL-23). Its key differentiators are the novel LANCL2 mechanism, oral/gut-restricted administration, and a biomarker-driven approach targeting specific patient subsets.